Brind.

Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.

4 reports, 1 independent Updated Sep 10
Gone quiet
Reports
4
Developments
2
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Compass Pathways announced that its Phase 3 trial for COMP360 successfully met the primary endpoint.

Who's involved

What this event is mainly about
Compass Pathways

How it developed

Newest first. Tap a step to see who reported it.
  1. COMP360 is being developed for TRD treatment.1 source
  2. Phase 3 trial success for Compass Pathways (COMP360).

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped